All In Biotech

Drug Trial Radar · NCT01314001

Pharmacogenetics of Nicotine Addiction Treatment

Pharmacogenetics of Nicotine Addiction Treatment (PNAT)

Last checked: Nov 19, 2026Latest source record: Mar 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,246 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,246

Actual

Start

Dec 2010

Primary completion

Dec 2013

Study completion Sep 2014

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Mar 14, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.

Conditions

  • Nicotine Addiction

Interventions

  • VareniclineDrug

    Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally

  • PlaceboDrug

    Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch

  • Transdermal NicotineDrug

    Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 7-day Point Prevalence Quit Rate at End-of-Treatment (EOT)Time frame: Week 11

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • University at Buffalo - State University of New York

    Buffalo, New York

  • Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center, University of Texas

    Houston, Texas

  • Centre for Addiction and Mental Health, University of Toronto

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.